SCHEMBL10323111

SCHEMBL10323111

C[Si](C)(C)CCOCn1nc(-c2cccc(NCc3cccc(Cl)c3)n2)c2cnc(NCCN3CCOCC3)nc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 2/20 0.47
▸ CCNT1 O60563 5/20 0.47
▸ MERTK Q12866 3/20 0.43
▸ MAPK8 P45983 1/20 0.41
▸ AXL P30530 1/20 0.39
▸ TYRO3 Q06418 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ CXCR4 P61073 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ CDK9 P50750 2/20 0.38
▸ EIF2AK2 P19525 1/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ JAK3 P52333 1/20 0.37
▸ PTK2 Q05397 1/20 0.37
▸ FGFR1 P11362 1/20 0.37
▸ SRC P12931 1/20 0.37
▸ FGFR2 P21802 1/20 0.37
▸ FGFR4 P22455 1/20 0.37
▸ FGFR3 P22607 1/20 0.37
▸ SCD O00767 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10323052 0.93 MERTK (0.44) FLT3CCNT1MERTKMAPK8AXL
SCHEMBL10322741 0.92 MERTK (0.49) FLT3CCNT1MERTKMAPK8AXL
SCHEMBL10322901 0.88 FLT3 (0.46) FLT3CCNT1MERTKMAPK8AXL
SCHEMBL10322157 0.88 MERTK (0.43) FLT3CCNT1MERTKMAPK8AXL
SCHEMBL10324360 0.86 MERTK (0.41) FLT3CCNT1MERTKAXLTYRO3
SCHEMBL10321987 0.83 MERTK (0.49) MERTKMAPK8AXLTYRO3EIF2AK2
SCHEMBL14664472 0.82 MERTK (0.48) MERTKMAPK8AXLTYRO3LMNA
SCHEMBL10322268 0.81 MERTK (0.54) MERTKMAPK8AXLTYRO3LMNA
SCHEMBL10322178 0.80 CCNT1 (0.54) FLT3CCNT1MAPK8LMNACXCR4
SCHEMBL10323692 0.79 MERTK (0.65) MERTKAXLTYRO3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362023-B2 Pyrazolo pyrimidines HOFFMANN-LA ROCHE INC. (US) 2013-01-29 — — US disclosed
US-8362023-B2 Pyrazolo pyrimidines HOFFMANN-LA ROCHE INC. (US) 2013-01-29 — — US disclosed
WO-2012098068-A1 PYRAZOLO PYRIMIDINES AS DYRK1A AND DYRK1B INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — WO disclosed
US-20120184508-A1 PYRAZOLO PYRIMIDINES BIODURO (BEIJING) COMPANY LTD. (CN) 2012-07-19 — — US disclosed
US-20120184508-A1 PYRAZOLO PYRIMIDINES BIODURO (BEIJING) COMPANY LTD. (CN) 2012-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184508-A1 PYRAZOLO PYRIMIDINES TYMS, TYMP, TP53 FLT3 1618/4885CCNT1 182/4885MERTK 2006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback